Biomarker Patient-Selection Radar

Solid Tumor Oncology Edition

Benchmark how biomarkers are used for patient selection, stratification, and treatment assignment in public solid tumor oncology trials.

Built from public interventional trial text and a conservative FDA CDx mapping. Threshold fragments and patent-density signals require expert clinical and regulatory review before use — this tool does not recommend patient-selection strategies or companion diagnostic approaches.

Open methodology Request custom biomarker scan

Biomarkers tracked

22

Curated biomarker dictionary entries in the current public screen.

Contexts detected

5

Biomarker + tumor-type + drug-context combinations identified from public trial text.

Linked trials

4

Interventional oncology trials linked into the current benchmark.

Inclusion-required contexts

4

Contexts where biomarker evidence appears to gate enrollment.

FDA CDx contexts

3

Contexts with matching local FDA companion diagnostic context.

Manual review required

0

Records that still need lower-confidence or contextual review.

Biomarker patient-selection table

Public context screen

Biomarker	Tumor type	Drug context	Role	CDx context	Thresholds	Patent density	Strategy	Confidence
PD-L1 expression	gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
KRAS G12C	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
KRAS G12D	NSCLC	Small Molecule Inhibitor	Inclusion Required	Fda Cdx Context Not Found	Low	Low	Low Public Signal	High
MSI-H / dMMR	colorectal cancer	Combination Therapy	Stratification	Fda Cdx Context Exists	Low	Low	Cdx Established Context	High
HER2 / ERBB2 expression	ovarian cancer	Monoclonal Antibody	Inclusion Required	Fda Cdx Context Exists	Moderate	Low	Cdx Established Context	High

Enrollment-required biomarkers

Selection signals

PD-L1 expression: PD-L1 expression is flagged as cdx established context because public trials show inclusion required evidence in 1 contexts. FDA CDx context exists.
KRAS G12C: KRAS G12C is flagged as low public signal because public trials show inclusion required evidence in 1 contexts. FDA CDx context should be reviewed manually.
KRAS G12D: KRAS G12D is flagged as low public signal because public trials show inclusion required evidence in 1 contexts. FDA CDx context should be reviewed manually.
HER2 / ERBB2 expression: HER2 / ERBB2 expression is flagged as cdx established context because public trials show inclusion required evidence in 1 contexts. FDA CDx context exists.

Stratification signals

Subgroup balancing

MSI-H / dMMR: MSI-H / dMMR is flagged as cdx established context because public trials show stratification evidence in 1 contexts. FDA CDx context exists.

FDA CDx context

Mapped contexts

PD-L1 expression: PD-L1 expression is flagged as cdx established context because public trials show inclusion required evidence in 1 contexts. FDA CDx context exists.
MSI-H / dMMR: MSI-H / dMMR is flagged as cdx established context because public trials show stratification evidence in 1 contexts. FDA CDx context exists.
HER2 / ERBB2 expression: HER2 / ERBB2 expression is flagged as cdx established context because public trials show inclusion required evidence in 1 contexts. FDA CDx context exists.

Drug development ahead of CDx context

Review queue

Sponsor-biomarker matrix

Sponsor views

Academic Cancer Center: 1 linked contexts
BioNova: 1 linked contexts
Merck Sharp & Dohme LLC: 1 linked contexts
Mirati Therapeutics: 2 linked contexts

Biomarker pages

Dictionary views

Biomarker access

Receive Biomarker Updates by Email

Use this form to compare biomarker patient-selection strategies, subscribe for email updates, choose CSV interests, or request a tumor-type-specific benchmark.